Yescarta demonstrates a five-year median duration of response, surpassing traditional therapies for relapsed/refractory follicular lymphoma. CAR-T cell therapy is potentially curative, with a plateau ...

Slovakia’s National Cancer Institute (NOÚ) is offering new hope to patients with otherwise incurable diagnoses, with the launch of innovative CAR T-cell therapy for lymphoma and leukaemia ...